Income investors sometimes take the route of finding the best income stocks to meet their needs based upon criteria like dividend safety, dividend growth potential or historical dividend streak. These
Microsoft, Danaher, Raytheon Technologies, Stryker Corporation and Vale are included in this Analyst Blog.

Top Stock Reports for Microsoft, Danaher & Raytheon Technologies

05:50pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Danaher Corporation (DHR) and Raytheon Technologies Corporation (RTX).

Here's Why You Should Retain Stryker (SYK) Stock For Now

04:13pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Stryker Corporation (NYSE: SYK) is a “mispriced” stock that has potential to offer lucrative returns over the long term, says Heather Brilliant. She’s the Chief Executive of Diamon Hill Capital
Stryker Corporation (NYSE: SYK) is a “mispriced” stock that has potential to offer lucrative returns over the long term, says Heather Brilliant. She's the Chief Executive of Diamon Hill Capital Ma
Heather Brilliant, Diamond Hill Capital Management president and CEO, joins CNBC's 'Squawk Box' ahead of the open on Tuesday to break down potential investment opportunities.

Should You Buy Stryker Stock Around $225?

08:00am, Friday, 16'th Sep 2022
Stryker stock (NYSE: SYK), a medical devices company, has seen a 15% fall this year, in line with the broader S&P500 index, down 17%.
Piper Sandler has decided to maintain its Overweight rating of Stryker (NYSE:SYK) and raise its price target from $250.00 to $260.00. Shares of Stryker are trading down 0.19% over the last 24 hours, a
Wells Fargo cut the price target on Cabaletta Bio, Inc. (NASDAQ: CABA) from $14 to $4. Wells Fargo analyst Derek Archila maintained the stock with an Overweight rating. Cabaletta Bio shares gained 0

Analyst Ratings for Stryker

05:34pm, Tuesday, 06'th Sep 2022 Benzinga
Within the last quarter, Stryker (NYSE:SYK) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 3 4 0 0 Last 30D 1 0 0

Tracking Terry Smith's Fundsmith 13F Portfolio - Q2 2022 Update

04:42am, Tuesday, 06'th Sep 2022 Seeking Alpha
Fundsmith filed their regulatory 13F Form on 8/15/2022. What were the latest stake disposals, increases and decreases? Click here to find out.

The All-Weather ETF Portfolio For Retirement

04:03am, Tuesday, 06'th Sep 2022 Seeking Alpha
A successful retirement can be attained by following some very simple suggestions. Click here for our all-weather ETF portfolio for retirement.

Why Stryker Remains a Top Health Care Name

11:01am, Thursday, 25'th Aug 2022
Stryker Corporation ( SYK , Financial) has long been one of my favorite health care names as the company provides some market-leading medical devices.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE